Enric Esmatjes

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +9

Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy

Tomás Berl, Lawrence G. Hunsicker, Julia B. Lewis et al. · Annals of Internal Medicine · 2003 · 397 citations

Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial

Marc A. Pohl, Samuel S. Blumenthal, D Cordonnier et al. · Journal of the American Society of Nephrology · 2005 · 373 citations

Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial

Tomás Berl, Lawrence G. Hunsicker, Julia B. Lewis et al. · Journal of the American Society of Nephrology · 2005 · 323 citations

Hypertension, Heart Failure, Cardiovascular Pharmacology +20

Metabolic profile of antipsychotic-naive individuals with non-affective psychosis

Emilio Fernández-Egea, Miquel Bernardo, Thomas Donner et al. · The British Journal of Psychiatry · 2009 · 240 citations · Full text